Published: 2019-04-26

Role of adipokines, oxidative stress, and endotoxins in the pathogenesis of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus

Pallavi M., Suchitra M. M., Alok Sachan, Lakshmi A. Y., Srinivasa Rao P. V. L. N.


Background: Type 2 diabetes mellitus (T2DM) is associated with chronic inflammation and oxidative stress, implicated in the pathophysiology of non-alcoholic fatty liver disease (NAFLD). Present study aimed to assess the role of adipokines, oxidative stress, and endotoxins in the pathogenesis of NAFLD in T2DM.

Methods: Present cross-sectional observational study included healthy controls (n=50; group 1); T2DM patients without NAFLD (n=50; group 2), T2DM patients with NAFLD (n=50; group 3). Study subjects were age and gender matched.

Results: Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), high sensitive C-reactive protein (hs-CRP), endotoxin, malondialdehyde (MDA) were significantly elevated and adiponectin, ferric reducing ability of plasma (FRAP), and glutathione (GSH) were significantly lower (p<0.001) in T2DM patients with NAFLD when compared to T2DM patients without NAFLD and controls. Endotoxin showed significant positive correlation with TNF-α (r=0.304; p<0.001), hs-CRP (r=0.193; p=0.018), and MDA (r=0.420; p<0.001), and significant negative correlation with adiponectin (r=-0.406; p<0.001). TNF-α and IL-6 showed significant positive correlation with MDA (r=0.526; p<0.001, r=0.229; p=0.005) and significant negative correlation with adiponectin (r=-0.396; p<0.001, r=-0.318; p<0.001), FRAP (r=-0.418; p<00.001, r=-0.170; p=0.038), and GSH (r=-0.353; p<0.001, r=-0.301; p<0.001).

Conclusions: Authors observed elevated endotoxin, oxidative stress, inflammation and lower adiponectin levels in T2DM subjects compared to controls. These changes were more pronounced in T2DM with NAFLD when compared to T2DM without NAFLD.  Lower adiponectin levels were found to be a better predictor of NALFD in T2DM and is associated with oxidative stress and systemic inflammation.


Adipokines, Endotoxins, Inflammation, Non-alcoholic fatty liver disease, Oxidative stress, Type 2 diabetes mellitus

Full Text:



Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10):721-8.

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. European J Endocrinol. 2005;152(1):113-8.

Mikako O, Hirofumi N. Diagnosis and evaluation of non-alcoholic fatty liver disease. Exp Diab Res. 2012.

Duseja A. Nonalcoholic fatty liver disease in India-a lot done, yet more required!. Indian J Gastroenterol. 2010;29(6):217-25.

Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterol. 1998;114:842-5.

Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Indian J Clinic Biochem. 2011;26(2):202-9.

Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physic India. 2009;57(3):205-10.

Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Molecular Sci. 2013;14(11):22933-66.

Adams LA, Harmsen S, Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105(7):1567.

American diabetes association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(1):S62-9.

Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Digestive Dis. 2008;9(2):108-12.

Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obesity. 1985;9(2):147-53.

Tukozkan N, Erdamar H, Seven I. Measurement of total malondialdehyde in plasma and tissues by high-performance liquid chromatography and thiobarbituric acid assay. Firat Tip Dergisi. 2006;11(2):88-92.

Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Analytical Biochem. 1996;239(1):70-6.

Ellman GL. Tissue sulfhydryl groups. Archives Biochem Biophysic. 1959;82(1):70-7.

Angulo P. Nonalcoholic fatty liver disease. New Eng J Med. 2002;346(16):1221-31.

Verrijken A, Francque S, Van Gaal L. The role of visceral adipose tissue in the pathogenesis of non-alcoholic fatty liver disease. European Endocrinol. 2011;7(2):96-103.

Kuppan G, Anjana RM, Deepa M, Paramasivam P, Chandrakumar S, Kaliyaperumal V, et al. Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Therapeut. 2012;14(2):152-8.

Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clinic Biochem. 2010;43(10-11):815-21.

Shams ME, Al-Gayyar MM, Barakat EA. Type 2 diabetes mellitus-induced hyperglycemia in patients with NAFLD and normal LFTs: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. Scientia Pharm. 2011;79(3):623-34.

Kumar R, Prakash S, Chhabra S, Singla V, Madan K, Gupta SD, et al. Association of pro-inflammatory cytokines, adipokines and oxidative stress with insulin resistance and non-alcoholic fatty liver disease. Indian J Med Res. 2012;136(2):229.

Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clinic Biochemist. 2007;40(11):776-80.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clinic Endocrinol Metabol. 2001;86(5):1930-5.

Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360(9326):57-8.

Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?. Am J Gastroenterol. 2003;98(12):2771-6.

Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol. 2009;46(2):113-8.

Lassenius MI, Pietiläinen KH, Kaartinen K, Pussinen PJ, Syrjänen J, Forsblom C, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 2011;34(8):1809-15.

Laugerette F, Vors C, Peretti N, Michalski MC. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Bioch. 2011;93(1):39-45.

Marshall JC. Glucose, insulin, coagulation: endotoxin as exohormone. Blood. 2008;112(1):6-7.

Keller P, Møller K, Krabbe KS, Pedersen BK. Circulating adiponectin levels during human endotoxaemia. Clinic Exp Immunol. 2003;134(1):107-10.

Byrne MM, Pluntke K, Wank U, Schirra J, Arnold R, Göke B, et al. Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia. European J Clinic Investiga. 1998;28(1):72-8.

Joseph AE, Saverymuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clinic Radiol. 1991;43(1):26-31.